Published in Gene Therapy Weekly, June 17th, 2004
"To evaluate anti-tumor effects of recombinant adenovirus p53, time-course p53, E6 expression, and cell growth inhibition were investigated in vitro and in vivo using cervical cancer cell lines such as CaSki, SiHa, HeLa, HeLaS3, C33A, and HT3," wrote W.S. Ahn and colleagues, Catholic University of Korea, College of Medicine.
"The cell growth inhibition was studied via cell count assay, MTT assay, and neutral red assay. After transfecting...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.